- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
New Blood Test Confirms Breast Cancer After Mammography
Pilot programs under way in Europe (November 25)
A study published in Biomarkers in Cancer has shown that new blood tests (Octava Blue and Octava Pink) can help to identify whether women who have had an abnormal mammography result actually have breast cancer. The study was conducted in the U.S., Italy, and Israel.
The analyses are the first in a new class of immune system-based blood tests that can detect the presence or absence of cancer by measuring ratios of autoantibodies produced in response to the presence of tumor-specific antigens. Pilot distribution programs are currently under way in Italy and are planned for other E.U. countries and Israel.
The Octava Blue test is designed to provide additional information to help clinicians interpret abnormal mammography results. Approximately 80% of the breast biopsies triggered by abnormal mammograms are negative, indicating that no cancer is actually present. According to the manufacturer (Eventus Diagnostics), the Octava Blue test helps confirm true positive mammography results with high accuracy and could lead to reductions in unnecessary biopsies caused by false positive results by 50% or more.
The second test, Octava Pink, is intended to provide additional information to the physicians of women who have received a negative mammography result. False negative results are common, particularly in the large population of women with dense breast tissue. Overall, screening mammograms miss an estimated 10% to 30% of breast cancers. Clinical studies have shown that the Octava Pink test detects true negative mammography results with high accuracy while identifying at least half of the missed breast cancers.
Source: Eventus Diagnostics; November 25, 2013.